Moberg Pharma Wins US Patent for Improved MOB-015 Dosing

PUBT · 4d ago
Moberg Pharma Wins US Patent for Improved MOB-015 Dosing
  • Moberg Pharma received a US patent on Nov. 3, 2026, covering improved dosing schedules for nail fungus treatment MOB-015.
  • Patent protection is expected to run through December 2041; the US is the first market to grant the improved-dosing patent.
  • Related patent applications remain under review in other markets.
  • The company holds all US rights to MOB-015 in the world's largest nail fungus market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moberg Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202611030200BITN____UKPR__SV_20261102-BIT-3155-0) on November 03, 2026, and is solely responsible for the information contained therein.